← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Tumor necrosis factor alpha (TNF-alpha) inhibitors
afelimomab
L04AB03
Forms & Strengths
- Solution for injection 10mg/mL
- Single-use vials
Adult Dosing
- Initial dose 10mg IV infusion over 15 minutes
- Maintenance dose 5mg IV infusion over 15 minutes
Pediatric Dosing
- Not established for use in pediatric patients
Indications
- Treatment of moderate to severe acute coronary syndrome
- Prevention of major adverse cardiac events
Mechanism of Action
- Selective inhibition of CD11b/CD18 integrin
- Reduces neutrophil adhesion and migration to the site of inflammation
Contraindications
- Hypersensitivity to afelimomab or other murine proteins
- History of anaphylactic reaction
Adverse Reactions
- Hypersensitivity reactions
- Increased risk of bleeding
- Anaphylaxis
Drug Interactions
- Increased risk of bleeding with anticoagulants and antiplatelets
- Concomitant use with other immunosuppressive agents not recommended
Curated Content: Needs Vetting Before Put to Clinical Use